Financial reports
NT 10-K
Notice of late annual filing
2 Jul 13
NT 10-Q
Notice of late quarterly filing
11 Feb 13
NT 10-Q
Notice of late quarterly filing
9 Nov 12
NT 10-Q
Notice of late quarterly filing
10 Aug 12
10-K
2012 FY
Annual report
14 Jun 12
10-Q
2012 Q3
Quarterly report
9 Feb 12
10-Q
2012 Q2
Quarterly report
19 Dec 11
Current reports
8-K
Departure of Directors or Certain Officers
6 Nov 13
8-K
KV Pharmaceutical Company Appoints Two New Board Members
18 Oct 13
8-K
KV Pharmaceutical Company Appoints Former Wyeth Pharmaceuticals President, Joe Mahady to Chairman of the Board
4 Oct 13
8-K
KV Pharmaceutical Company Completes Reorganization and Successfully Emerges from Chapter 11 with $375 Million Recapitalization
23 Sep 13
8-K
United States Bankruptcy Court Southern District of New York
23 Sep 13
8-K/A
KV Pharmaceutical Company Completes Reorganization and Successfully Emerges from Chapter 11 with $375 Million Recapitalization
23 Sep 13
8-K
United States Bankruptcy Court Southern District of New York
5 Sep 13
8-K
Regulation FD Disclosure
21 Aug 13
8-K
Ther-Rx Corporation Announces the Availability of Clindesse® (Clindamycin Phosphate) Vaginal Cream, 2% for Prescribing
8 Aug 13
8-K
Regulation FD Disclosure
19 Jul 13
Registration and prospectus
15-12B
Securities registration termination
9 Apr 14
15-12G
Securities registration termination
15 Oct 13
D
$260.88M in equity, sold $260.88M, 28 investors
25 Sep 13
25-NSE
Exchange delisting
22 Aug 12
RW
Registration withdrawal request
9 Aug 12
S-1
IPO registration
31 Jul 12
D
Indefinite amount in equity, sold $210K, 1 investor
18 Jun 12
424B3
Prospectus supplement
9 Feb 12
424B3
Prospectus supplement
9 Feb 12
424B3
Prospectus supplement
19 Dec 11
Proxies
DEFA14A
Additional proxy soliciting materials
20 Aug 12
DEFA14A
Additional proxy soliciting materials
3 Aug 12
DEF 14A
Definitive proxy
26 Jul 12
DEF 14A
Definitive proxy
26 Jul 11
DEF 14A
Definitive proxy
7 May 10
DEF 14C
Information statement
28 Jan 10
PRE 14C
Preliminary information
14 Jan 10
DEF 14C
Information statement
2 Dec 09
PRE 14C
Preliminary information
16 Nov 09
DEF 14A
Definitive proxy
29 Jul 08
Other
CT ORDER
Confidential treatment order
10 Feb 12
EFFECT
Notice of effectiveness
26 Aug 11
CORRESP
Correspondence with SEC
24 Aug 11
CORRESP
Correspondence with SEC
24 Aug 11
CORRESP
Correspondence with SEC
24 Aug 11
UPLOAD
Letter from SEC
20 Jul 11
EFFECT
Notice of effectiveness
15 Jul 11
EFFECT
Notice of effectiveness
13 Jul 11
UPLOAD
Letter from SEC
28 Mar 11
CORRESP
Correspondence with SEC
10 Mar 11
Ownership
11-K
Annual report of employee stock purchases
27 Sep 13
SC 13G
K-V Pharmaceutical Co
26 Sep 13
SC 13D/A
KV Pharmaceutical Co /De/
7 Aug 13
SC 13D
KV Pharmaceutical Co /De/
5 Aug 13
SC 13D
KV Pharmaceutical Co /De/
1 Aug 13
SC 13D
KV Pharmaceutical Co /De/
24 Jul 13
SC 13D
KV Pharmaceutical Co /De/
16 Jul 13
SC 13D
KV Pharmaceutical Co /De/
12 Jul 13
SC 13D/A
AmediusTec Ltd.
28 Sep 12
11-K
Annual report of employee stock purchases
27 Sep 12